Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women

This study is enrolling participants by invitation only.
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
First received: May 12, 2009
Last updated: May 29, 2009
Last verified: May 2009
Recurrent urinary tract infections (UTI) are a problem for postmenopausal women. The aim of this trial is to evaluate the effectiveness of lactobacilli in combination with low dose estriol for preventing recurrent urinary tract infections in postmenopausal women.

Condition Intervention Phase
Urinary Tract Infections
Drug: Gynoflor E (low dose estriol with lactobacillus)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Incidence of urinary tract infection [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • vaginal pH [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • lactobacillus colonization [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 142
Study Start Date: May 2009
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gynoflor Drug: Gynoflor E (low dose estriol with lactobacillus)
The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
Other Name: Gynoflor E vaginal tablet
No Intervention: Control


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal woman
  • History of urinary tract infection
  • Agree to abstain from self-medication with antibiotics for UTI symptoms
  • Agree to abstain from the use of any other intra-vaginal product
  • Capable of providing informed consent

Exclusion Criteria:

  • Ovarian cancer, cervical cancer, breast cancer
  • Estrogen treatment within last 2 years
  • Vaginal bleeding
  • Antibiotic therapy fewer than three days prior to randomization visit
  • Known congenital urologic or gynecologic abnormalities
  • Indwelling urinary catheter
  • Thromboembolic disease
  • Uncompensated liver disease
  • Immunosuppressive drug within 60 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00900653

Korea, Republic of
Yonsei University College of Medicine
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
  More Information

Responsible Party: Jun Yong Choi, Yonsei University College of Medicine
ClinicalTrials.gov Identifier: NCT00900653     History of Changes
Other Study ID Numbers: 4-2009-0022 
Study First Received: May 12, 2009
Last Updated: May 29, 2009
Health Authority: South Korea: Institutional Review Board

Keywords provided by Yonsei University:
urinary tract infections

Additional relevant MeSH terms:
Communicable Diseases
Urinary Tract Infections
Urologic Diseases

ClinicalTrials.gov processed this record on May 30, 2016